10. AZD7442 synthetic antibodies could offer long-lasting protection
Developer: AstraZeneca (LON:AZN)
Description: AZD7442 combines two monoclonal antibodies to home in specific SARS-CoV-2-produced antigens. The synthetic antibodies could offer protection for six months to a year, according to an AstraZeneca press release.
Development status: AZD7442 is undergoing a Phase 3 trial
Filed Under: clinical trials, Drug Discovery, Infectious Disease